Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Innovation Pharmaceuticals, Inc."
Count: 15
Selected: 0
NCT04784897A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
NCT04240223A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers
NCT02324335Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
NCT03042702A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
NCT02949388Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
NCT02101216Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
NCT02052388Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
NCT01990209Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
NCT02168101Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
NCT01871675Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
NCT00193557Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
NCT01056276Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
NCT00633594Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
NCT01029730Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
NCT00193232Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer